SIPRIANUS UGROSENO YUDHO BINTORO, 090810014D (2012) MUTASI GEN TIROSIN KINASE Bcr-Abl PADA CHRONIC MYELOGENOUS LEUKEMIA Bcr-Abl POSITIF FASE KRONIK YANG TIDAK RESPONS LENGKAP MOLEKULER TERHADAP INHIBITOR TIROSIN KINASE. Disertasi thesis, UNIVERSITAS AIRLANGGA.

Preview	Text (ABSTRAK) gdlhub-gdl-s3-2013-bintorosip-23246-5.abst-t.pdf Download (93kB) | Preview
	Text (FULLTEXT) Binder1bintorosip.pdf Restricted to Registered users only Download (1MB) | Request a copy

Abstract

Background: It is important to determine types of mutations and the pattern of ABL kinase gene mutations that occur in CML patients with positive BCR- ABL which had incomplete molecular response to first generation tyrosine kinase inhibitor. Objective: To determine the point mutation C944T, T1052C, T932C in kinase domain of the Bcr-Abl gene and the influence of the number of point mutations to Bcr-Abl/G6PDH. Method: Observational clinical and laboratories study. Blood samples of CML patients BCR-ABL positive who received treatment for more than 18 months. Results Major response to the first generation tyrosine kinase inhibitors is complete hematology response (90%). (2) The majority (60%) of molecular response is CMR. (3) Most of the patients showed transcripts of Bcr-Abl b3a2 are 30 patients, b2a2 are 9, and only one patient showed b2a3.(4). Profiles tested of the kinase domain mutations are C944T, T932C, and T1052. (5). : The analysis of C944T, T932C and T1052C significantly influence the response of treatment. (7). The new findings in this study are (1). The incidence of T932C mutation are quite high.(2) The type of the Bcr-Abl transcript will affect the increase of leucocytes (3) The number of mutations in the Bcr-Abl kinase domain affects to the blast and the ratio Bcr-Abl/G6PDH

Actions (login required)

View Item